NCT02127307

Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.

An Open-Label, Multicenter, Phase 4 Study to Demonstrate the Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 964 (actual)
• Sponsor: GE Healthcare · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This aim of the study is to investigate the prognostic usefulness of AdreView™ imaging to identify those subjects with New York Heart Association (NYHA) Class II or III HF who will die during 60 months of follow-up from the date of administration of AdreView™ in prior studies MBG311, MBG312, or MBG312C (hereafter included in MBG312).

Conditions

• Heart Failure (HF)

Timeline

• Start date: 2014-02-01
• Primary completion: 2014-12-01
• Completion: 2016-04-01
• First posted: 2014-04-30
• Last updated: 2017-03-28
• Results posted: 2017-03-28

Locations

1 site across 1 country: United States